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Introduction: 
Historically, there have been few treatment options for children with severe, refractory bladder 
and bowel dysfunction (BBD). Sacral neuromodulation (SNM) continues to show promising 
results in this challenging pediatric population with recalcitrant lower urinary tract symptoms.  At 
our institution, we have begun offering explantation to those with persistent improvement after 
>6 months of having device turned off.  We hypothesized that 1.) SNM explantation for cure
increases with extended follow-up, and 2.) those explanted for cure would have improved
symptoms and quality of life when compared to those explanted for complication.
Materials & Methods: 
We retrospectively reviewed all consecutive patients <18 years old who 
underwent SNM placements at our institution (2012-2017).  We excluded those without the 
second stage procedure.  Reasons for device explantation were categorized as: cure (resolution 
of symptoms with the device turned off for at least 6 months), or a complication (e.g. infection, 
need for MRI, or pain).  Non-parametric tests and survival analysis were used for analysis to 
account for differential follow-up time. Of those explanted, surveys were electronically sent to 
assess BBD severity, and overall quality of life.  
Results: 
Of 67 children who underwent a first stage procedure, 62 (92.5%) underwent a second stage 
procedure.  61 met inclusion criteria (68.9% female, 29.5 % with previous filum section, median 
age at implantation 10.3 years old).  During follow-up (median 2.3 years), 12 patients (19.7 %) 
had the SNM exchanged/revised due to lead fracture/breakage and return of urinary 
symptoms.  To date, 50 patients remain with their SNM implanted, and 11 have been explanted. 
Adjusting for follow-up time, the risk of explantation was 6.5% at 2 years (2.2% for cure, 4.3% 
for complications) (Figure 1).  Explantation increased to 24.5% at 3 years (16.5% for cure, 8.0% 
for complications) and 40.4% at 4 years (32.4% for cure, 8.0% for 
complications).  Questionnaires were collected on patients post explant (median 2.2 years), with 
improvement in those explanted for cure compared to complication (Figure 2). 
Discussion: 
SNM explantation for cure is a novel concept previously not described in the literature.  
Limitations of this study include the relatively small numbers, and lack of objective data in the 
cohort that remains with SNM device implanted. 
Conclusion: 
SNM is a safe, viable option for the pediatric patient with refractory bladder 
dysfunction.  Furthermore, SNM explantation for cure is an option with increasing likelihood after 
two years. 
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Introduction: 
 
Within the practice of pediatric urology, lower urinary tract dysfunction (LUTD), bowel 
dysfunction, and, more generally, bladder and bowel dysfunction (BBD) are frequent diagnoses 
of varying severity.  Children often present with symptoms of increased or decreased urinary 
frequency, urgency, nocturia, hesitancy, straining, weak stream, intermittency, urinary 
incontinence, and/or dysuria.  These symptoms correlate with urodynamic findings of detrusor 
overactivity, detrusor sphincter discoordination, and an otherwise normal neurologic history and 
physical exam [1].   
 
First line therapy in this population consists of behavioral modification, or urotherapy [2, 3].  
Also, constipation needs to concurrently be addressed in order to rule out the effects of rectal 
distension upon bladder function, given the previously described pelvic organ “cross-
sensitization” [4].  Previous authors have described “cross-sensitization” as the “transmission of 
noxious stimuli from a directly affected pelvic organ to an adjacent normal structure.”  For those 
with persistent, refractory symptoms, techniques of biofeedback, focused physical therapy, 
anticholinergics, alpha blockers, and noninvasive, transcutaneous neurostimulation may be 
considered [2].   
 
In 2004, SNM (a therapeutic option consisting of permanent electrical stimulation of the sacral 
nerves at the S3 level using an implantable pulse generator device ) was first reported as a 
potential option in the pediatric patient population [5].  In this study, children (mainly with spina 
bifida) were randomized to SNM implantation or control (mainly intermittent catheterization, 
anticholinergics, and bulking agent for continence or reflux), with some evidence of clinical 
improvement, however, urodynamic differences were not statistically significant.  Later, larger 
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studies affirmed an improvement in treating neurologically normal children’s refractory bladder 
and bowel symptoms as well as quality of life [6-10].  Limited data exists as to the “life 
expectancy” of the SNM in the pediatric population.  Dwyer et al described explantation rates in 
children (38 devices at median 2.36 years, 12 for complete symptom resolution).  We are 
unaware of any other data in the pediatric or adult SNM literature that describes voluntary 
explant for “cure.”  Within the pediatric realm, families that have experienced a profound relief of 
symptoms following SNM implantation seek prognostic data as to when this device may stop 
having a therapeutic benefit and be explanted, and/or require further surgery.   
 
We hypothesized that 1.) SNM explantation for cure and complications increases with extended 
follow-up, and 2.) those explanted for cure would have improved symptoms and quality of life 
when compared to those explanted for complication. 
 
Materials & Methods: 
 
After obtaining approval from our institutional review board, we retrospectively reviewed all 
children (<18 years of age) treated at our institution for refractory bladder dysfunction with 
implantation of a SNM device between November 2012 and September 2017.  Those 
considered refractory to conservative measures had not improved after a prolonged trial of 
behavioral modification, dietary modification, biofeedback/focused physical therapy, aggressive 
treatment of concomitant constipation, and pharmacologic therapy with anticholinergics that 
lasted for 2 years or more.  Only after all of these more conservative options were exhausted 
was SNM offered.  In addition, a spinal MRI was obtained on all patients to exclude a previously 
unrecognized, occult spinal dysraphism (OSD) by screening for a low lying conus and/or 
fatty/thickened filum terminale [11].  Those with any signs of a tethered cord were referred to 
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neurosurgery for possible filum section/detethering.  However, we included in our analysis those 
with persistent symptoms, despite filum section, and treated with SNM.  We excluded patients 
who did not go on to have the second stage procedure performed due to less than 50% 
improvement of symptoms following 2-week trial.  The most recent follow up was recorded of all 
patients in the cohort.   
 
Operative Procedure: 
 
Children were treated with implantation of an InterStim II® device (Medtronic, Inc., Minneapolis, 
MN, USA). The first stage was performed in an operating room under general anesthesia with 
the patient in the prone position, using a tined lead placed adjacent to the S3 nerve root.  This is 
confirmed fluoroscopically, as well as with confirmation of the bellows response and plantar 
flexion of the great toe with stimulation on the ipsilateral side.  Patients and their families then 
use an external generator for a 2-week trial period.  During this trial period, patients’ families \ 
are diligently called by our support staff to obtain a symptom diary, and provide as needed 
adjustments to their SNM device.  Those that describe a significant (>50 %) improvement in 
their bladder dysfunction symptoms are given the option to proceed to the second stage, 
involving placement of an internalized generator in the subcutaneous space in the contralateral 
superior gluteal fold.  
 
Following implantation, we keep in close contact with all families with regular follow up.  For 
those with complete response after at least one year after implantation, we offer a trial of turning 
the device off to check for symptom resolution.  Subsequently, in those with complete success 
with the device off for >6 months, we offered explantation.  We originally had planned for 1 year, 
but some families requested removal earlier, given persistent improvement. 
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Outcomes 
 
We retrospectively collected demographic and SNM surgery data.  For those who underwent 
device explantation, the indication for explantation was noted.  We categorized indications as 
cure (resolution of symptoms with device off for >6 months) or complication (infection, need for 
an MRI for further neurosurgical evaluation, or refractory pain in the general area).  To account 
for differential follow-up times, we performed a Kaplan-Meier survival analysis to graphically 
examine the impact of explantation for these two reasons while adjusting for differential follow-
up time.  In order to assess long-term symptom control, we contacted the patients that have 
been explanted, and sent them electronic questionnaires that included the Vancouver Symptom 
Score for Dysfunctional Elimination Syndrome (VSSDES) and the Pediatric Urinary 
Incontinence quality of life questionnaire (PinQ) to objectively quantify the degree of BBD, and 
the  effect of their current level of bladder dysfunction upon their wellbeing, respectively [12, 13].  
We also collected PedsQL scores to evaluate overall health-related quality of life currently [14].   
 
Results: 
 
Of the 67 children who underwent a first stage procedure, 62 (92.5%) underwent a second 
stage procedure.  After excluding 1 child that was lost to follow-up, 61 met inclusion criteria 
(68.9 % female, 29.5 % status post filum section, median 10.3 years old).  Median follow-up 
time was 2.3 years.  Children who did and did not undergo a second stage procedure were 
similar in age at implantation and gender (p>=0.11) (Table 1).  During follow-up, 12 patients 
(19.4 %) that went on to have the second stage procedure had the SNM exchanged/revised due 
to lead fracture/breakage and return of urinary symptoms.  Subsequently, we compared those 
explanted (11) to those that remained with the device in place (50) (Table 2).  The follow-up 
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time was significantly longer in the explanted group, due to the criteria required (described 
above) for explantation to be offered.  Otherwise, all other demographics were similar.   
 
Explantation Analysis 
 
We performed a survival analysis of the 61 children meeting inclusion criteria to evaluate the 
likelihood and time course of explantation for different indications. To date, 50 patients remain 
with their SNM implanted and 11 have been explanted (8 for cure, 3 for complications).  No 
devices in this cohort were explanted for lack of response/effect.   We found that most 
explantations were performed after 2 years of follow-up (Figure 1).  Adjusting for differential 
follow-up time, the risk of explantation was 6.5% at 2 years (2.2% for cure, 4.3% for 
complications, Table 3).  Explantation increased to 24.5% at 3 years (16.5% for cure, 8.0% for 
complications) and 40.4% at 4 years (32.4% for cure, 8.0% for complications).  
 
Measuring Quality of Life: 
We then looked to the post explantation questionnaires.  These were administered a median of 
1.6 and 2.5 years following explant in the cure and complication cohorts, respectively.  Of the 11 
patients with a SNM explant, we were able to contact 8 (unable to contact 3 explanted for cure).  
For the VSSDES, we found a median score of 9 in those explanted for cure (max/worst score of 
56).  This compared to 21 in the three explanted for complication.  The PINQ scores also were 
markedly different.  Of those explanted for cure, the median PINQ score was 12, as compared 
to 59 in the complication group (max/worst score possible of 80).  Lastly, the general quality of 
life was also documented in those explanted for complication and cure using the PedsQL 
questionnaire (max score of 100 considered maximum quality of life).  Again, those explanted 
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for cure demonstrated a marked difference with a median score of 83.3, as compared to 46.7 in 
those explanted for complication. 
 
Discussion: 
 
This retrospective analysis of pediatric patients with severe, refractory bladder symptoms 
provides some needed prognostic information for providers as well as parents.  Although 
previous studies have demonstrated the efficacy of SNM in this population [6, 7, 10, 15, 16], our 
data would further suggest that explantation of the device after consistent symptom 
improvement is not only possible, but clinically effective, and durable. 
 
Lloyd et al. discuss their experience with explantation in the adult population [17].  We could not 
find mention of this anywhere else in the adult literature.  In their study, 90 patients underwent 
device removal after implantation.  Of these, removal occurred for MRI (21 patients, 23 %), lack 
of efficacy (51 patients, 57 %), infection (10 patients, 11 %), and pain (8 patients, 9 %).  
Interestingly, one third (7) of the MRI group reported preoperative, suboptimal symptom control, 
and only 10 % (2) sought device replacement following explant.  Of the remaining 19 who had 
the device removed prior to an MRI, 7 sought pharmacologic therapy, 3 intermittent 
catheterization, 2 Botulinum toxin, one local urologic care, one cystectomy/ileal conduit, one 
died, and 4 were lost to follow up.    
 
Our findings in the pediatric population would suggest that there is a sustained benefit after 
therapy. Unfortunately, many questions remain to be answered as to primary mechanism by 
which SNM works at all.  The theoretical advantage of electrical neurostimulation use in 
childhood compared to adults is the increased neuroplasticity of central and peripheral nervous 
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systems with the potential for altered long-term outcomes [16].  With increasing evidence in 
adult LUTS literature, these adult conditions (overactive bladder, urgency, etc.) may be inherent 
and longstanding [16, 18-21].  This could explain why, in the adult population, LUTS seem to 
invariably return after explant [17].  One wonders, if this effect is sustained, perhaps we could 
alter or eliminate future, adult LUTS with initial treatment in childhood.  
 
Dwyer et al. provide some valuable insights in their 10-year experience in the pediatric 
population [6].  Interestingly, despite 99/105 (94 %) of children experiencing improvement of at 
least 1 symptom following implantation, they noted reoperations in as many as 59/105 (56 %), 
mostly due to device malfunction.  Our data suggested a reoperation rate of 12/61 (19.7 %).  
They noted explantation in 38/105 (35 %), mainly for complete symptom resolution at a median 
of 2.4 years after implantation.  It was unclear whether a trial period with device turned off was 
performed, and how those explanted in their cohort fared following explant.  As noted above, we 
had an explant rate of 11/61 (18.0 %) after a median follow up of 2.22 years.  Of note, unlike 
Dwyer et al, we have always employed the 2 stage technique. 
 
The strength of our study is its robust, pediatric cohort with intermediate follow-up and a subset 
of post-explant cured patients. To our knowledge, this durable response has not been 
previously described in the pediatric neurourologic literature.  In addition, we used multiple 
measures (PEDS QL, Vancouver questionnaire, PINQ) to objectively measure changes in 
quality of life and LUTS.   
 
Weaknesses of this study include the inherent weaknesses of many retrospective studies.  An 
unrecognized, confounding variable could influence who was offered and consented to device 
explant.  Despite being offered explant, families/parents can choose whether to remain with 
their device, and if ever to explant the device.  In addition, our population is small and somewhat 
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heterogeneous with a subset previously treated with filum section.  Also, survey results were 
sometimes difficult to obtain, and the most difficult to contact (3/11 explanted patients) were, 
perhaps, paradoxically, those that had the greatest improvement following implantation.  Lastly, 
follow up remains short for those explanted, and theoretically, symptoms could return. 
 
Conclusion: 
 
SNM is a viable option for the pediatric patient with refractory bladder dysfunction after all other 
less invasive options have been exhausted.  Over 90% of patients selected for SNM undergo 
permanent device placement. SNM has low explantation rates for complications, a high 
likelihood of continued benefit from the device, with a progressively increasing chance for 
explantation for cure beginning 2 years after implantation.  Further study of this population will 
be interesting to see if this benefit has continued durability. 
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Table 1:  
 
 Did not complete 2nd stage (5) Completed 2
nd
 Stage 
(62) 
P value 
Female 3 (60.0 %) 43 (69.3 %) 0.65* 
Median age at 
implantation 
 (1st Q, 3
rd
 Q)) 
8.1 years 
(7.9, 8.2) 
10.1 years 
(7.8, 12) 
0.09** 
Median Follow up 
(1st Q, 3
rd
 Q) 
0.54 years 
(0.4, 1.8) 
2.22 years 
(1, 3) 
0.14** 
Previous Filum Section 1 (20 %) 18 (29 %) 0.99* 
*Using Fischer’s exact test. 
**Using simple T-test. 
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Table 2: 
  
 Device Remains (51) Device Explanted (11) P Value 
Female 34 (66.7 %)  9 (81.8 %) 0.48 
Previous Filum Section 17 (33.3 %) 1 (9.1 %) 0.15 
Revision Rate 8 (15.7 %) 4 (36.4 %) 0.20 
Median age at Implant 
(1
st
 Q, 3
rd
 Q) 
9.9 (7.7, 12.1)) 10.4 (7.8, 11.6) 0.72 
Median Follow up (1
st
 
Q, 3
rd
 Q) 
2.1 years (1.0, 2.8) 3.2 years (2.4, 3.5) 0.001 
Median time to Explant 
(1
st
 Q, 3
rd
 Q) 
- 2.6 years (1.4, 3.0)  
(Excluded those without 2
nd
 stage.) 
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Table 3. 
 
Risk of sacral neuromodulation device explantation due to resolution of symptoms or 
complications. Note: percentages are based on survival analysis calculations adjusting 
for decreasing number of patients remaining in follow-up over the course of the study. 
Time after SNM 
implantation 
(years) 
Number of 
patients 
followed in 
this time-
frame 
Remain with 
SNM 
Explanted for 
cure 
Explanted for 
complication 
1 year 60 (100.0%) 59 (98.2%) 0 (0.0%) 1 (1.8%) 
2 years 47 (78.3%) 45 (93.5%) 1 (2.2%) 1 (4.3%) 
3 years 35 (58.3%) 30 (75.5%) 4 (16.5%) 1 (8.0%) 
4 years 12 (20.0%) 10 (59.6%) 2 (32.4%) 0 (8.0%) 
5 years 5 (8.3%) 4 (39.7%) 1 (52.3%) 0 (8.0%) 
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Figure 1:  Kaplan-Meier Survival Curve for all Implanted SNM Devices 
 
 
Figure. Incidence of sacral neuromodulation device explantation due to complications or resolution of symptoms. 
 
Explanted for complication 
Explanted for cure 
Device remains implanted 
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Figure 2:  Explant Surveys for those Explanted for Cure and Complication 
 
 
Figure. ^ Raw scores in the cure cohort were: 5, 8, 9, 15, 16 
*Based upon cutoff score of 11 suggested by Afsar, et al.2 
** Based upon Thibodeau et al’s proposed mild=<21, moderate=21-50, m and severe>503 
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